期刊文献+

医院丙肝微消除模式的建立与应用成效

Establishment and application effect of micro-elimination model of hepatitis c in hospital
下载PDF
导出
摘要 目的建立医院丙肝微消除模式并分析其在丙肝防治工作中的应用成效。方法以广西贵港市某三甲医院为例,通过部门分工、协调合作、能力建设多方面构建丙肝微消除模式,分析项目实施前(2021年)、项目实施后(2022年)两组抗-HCV筛查率、HCV RNA检测率、DAA治疗率、丙肝治愈人数的变化。结果2022年与2021年相比,抗-HCV筛查率由78.8%上升到81.2%,HCV RNA检测率由75.1%上升到97.8%,DAA治疗率由19.4%上升到57.3%,差异均具有统计学意义(P<0.05);丙肝治愈人数由61人上升到231人,成效明显。结论在医院建立丙肝微消除模式可显著提高抗-HCV筛查率、HCV RNA检测率、DAA治疗率,促进更多丙肝患者的治愈,有助于加快中国丙肝消除战略的进程,值得推广应用。 Objective To establish a micro-elimination model of hepatitis C in hospital and analyze its application effect in hepatitis C prevention and control.Methods A tertiary hospital in Guigang,Guangxi was taken as an example to construct a micro-elimination model of hepatitis C through division of labor,coordination and cooperation,and capacity building.The changes of anti-HCV screening rates,HCV RNA testing rates,DAA treatment rates,and the number of patients cured before(2021)and after(2022)the implementation of the project were analyzed.Results Compared with 2021,anti-HCV screening rate increased from 78.8%to 81.2%,HCV RNA testing rate increased from 75.1%to 97.8%,DAA treatment rate increased from 19.4%to 57.3%,and the number of people cured increased from 61 to 231 in 2022.The differences were all statistically significant(P<0.05).Conclusion The establishment of hepatitis C micro-elimination model in hospitals can significantly improve the anti-HCV screening rate,HCV RNA detection rate,DAA treatment rate,promote the cure of more hepatitis C patients,and help to accelerate the process of hepatitis C elimination strategy in China,which is worthy of popularization and application.
作者 陆彦盟 李仕雄 向文耀 蒙梦兰 黄少美 吕日英 LU Yanmeng;LI Shixiong;XIANG Wenyao;MENG Menglan;HUANG Shaomei;LV Riying(Guangxi Guigang People’s Hospital,Guigang 537100,China)
机构地区 贵港市人民医院
出处 《现代医院》 2024年第4期651-653,共3页 Modern Hospitals
基金 贵港市科学研究与技术开发项目(贵科计2117016)。
关键词 医院 丙肝 微消除 应用成效 Hospital Hepatitis C Micro-elimination Effectiveness of application
  • 相关文献

参考文献11

二级参考文献62

  • 1Huiying Rao,Xingxiang Yang,Youwen Tan,Qin Ning,Daokun Yang,Jiefei Wang,Yongfeng Yang,Sujun Zheng,Dongliang Yang,Jinlin Hou,Qing Xie,Caiyan Zhao,Lunli Zhang,Xiaorong Mao,Tong Sun,Lang Bai,Fuchun Zhang,Jinglan Jin,Yingren Zhao,Maorong Wang,Wen Xie,Yingjie Ma,Jun Quan,Xuebing Yan,Ping An,Feng Lin,Jidong Jia,Xiaoxuan Hu,Zuojiong Gong,Jie Wu,Yongping Chen,Zhansheng Jia,Minghua Lin,Guiqiang Wang,Yueyong Zhu,Yingjun Zhang,Hongming Xie,Lin Luo,Qingyun Ren,Rui Huang,Lai Wei.Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis[J].Journal of Clinical and Translational Hepatology,2020,8(3):255-261. 被引量:3
  • 2Lai Wei,Jia Shang,Yuanji Ma,Xiaoyuan Xu,Yan Huang,Yujuan Guan,Zhongping Duan,Wenhong Zhang,Zhiliang Gao,Mingxiang Zhang,Jun Li,Jidong Jia,Yongfeng Yang,Xiaofeng Wen,Maorong Wang,Zhansheng Jia,Bo Ning,Yongping Chen,Yue Qi,Jie Du,Jianning Jiang,Lixin Tong,Yao Xie,Jinzi JWu.Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis C[J].Journal of Clinical and Translational Hepatology,2019,7(3):221-225. 被引量:13
  • 3Xiaoyuan Xu,Bo Feng,Yujuan Guan,Sujun Zheng,Jifang Sheng,Xingxiang Yang,Yuanji Ma,Yan Huang,Yi Kang,Xiaofeng Wen,Jun Li,Youwen Tan,Qing He,Qing Xie,Maorong Wang,Ping An,Guozhong Gong,Huimin Liu,Qin Ning,Rui Hua,Bo Ning,Wen Xie,Jiming Zhang,Wenxiang Huang,Yongfeng Yang,Minghua Lin,Yingren Zhao,Yanhong Yu,Jidong Jia,Dongliang Yang,Liang Chen,Yinong Ye,Yuemin Nan,Zuojiong Gong,Quan Zhang,Peng Hu,Fusheng Wang,Yongguo Li,Dongliang Li,Zhansheng Jia,Jinlin Hou,Chengwei Chen,Jinzi JWu,Lai Wei.Efficacy and Safety of All-oral,12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naive Noncirrhotic HCV Genotype 1 Patients:Results from a Phase 2/3 Clinical Trial in China[J].Journal of Clinical and Translational Hepatology,2019,7(3):213-220. 被引量:15
  • 4Mohammad Irshad,Dhananjay Singh Mankotia,Khushboo Irshad.An insight into the diagnosis and pathogenesis of hepatitis C virus infection[J].World Journal of Gastroenterology,2013,19(44):7896-7909. 被引量:56
  • 5丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 6Centers for Disease Control and Prevention. Sexually transmitteddiseases treatment guidelines. Available fi'om: http://www, cdc. gov/mmwr/preview/mmwrhtml/rr5 91 2al. htm? s_cid:rr5912al_e. Accessed April 30,2012.
  • 7Ford C, Halliday K, Foster G, et al. Guidance for the prevention, testing, treatmdnt and management of hepatitis C in primary care. 1st edition. Available at www. smmgp, org. uk/htm/guidance.php. Accessed April 30,2012.
  • 8Washington State Department of Health. Hepatitis C reporting and surveillance guidelines in Washington. Available from: http://www. doh. Wa. gov/notify/guidelines/heptitisc, pdf. Accessed April 30, 2012.
  • 9Kim S, Kim J H, Yoon 5, et al. Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection. J Clin Microbiol. 2008;46(12):3 919-923.
  • 10Omata M, Kanda T, Yu ML, et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int. 2012;6(2):409-435.

共引文献172

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部